Table 1. The incident cases and age-standardized incidence rates from pancreatic cancer, as well as their temporal trends by sex and super-region from 1990 to 2019.
| 1990 | 2019 | 1990–2019 | ||||
|---|---|---|---|---|---|---|
| Incident cases No. (95% UI) | ASIR per 100,000 (95% UI) | Incident cases No. (95% UI) | ASIR per 100,000 (95% UI) | EAPC of ASIR (95% CI) | ||
| World | ||||||
| Total | 197347.99 (188604.03, 203971.11) | 5.22 (4.96, 5.46) | 530296.75 (486175.15, 573635.16) | 6.57 (6.00, 7.09) | 0.83(0.78,0.87) | |
| Female | 93295.72 (88533.66, 96901.56) | 4.52 (4.26, 4.79) | 250393.36 (223820.17, 275352.20) | 5.71 (5.11, 6.28) | 0.81(0.77,0.85) | |
| Male | 104052.26 (99197.91, 108990.84) | 5.99 (5.71, 6.26) | 279903.39 (256008.81, 303427.20) | 7.49 (6.85, 8.12) | 0.84(0.79,0.90) | |
| CEEECA | ||||||
| Total | 32305.61 (31076.57, 33659.81) | 6.79 (6.52, 7.78) | 53494.69 (49215.57, 57659.31) | 8.51 (7.83, 9.16) | 0.65(0.53,0.81) | |
| Female | 15239.61 (14368.71, 16421.21) | 5.14 (4.85, 5.54) | 25387.32 (22860.28, 28017.14) | 6.59 (5.93, 7.29) | 0.78(0.65,0.92) | |
| Male | 17066.00 (16616.03, 17968.09) | 9.20 (8.95, 9.69) | 28107.36 (25556.04, 30675.99) | 11.04 (10.04, 12.56) | 0.49(0.32,0.65) | |
| HI | ||||||
| Total | 105277.71 (100849.78, 107499.88) | 8.72 (8.36, 8.91) | 220848.67 (196750.32, 242213.24) | 10.19 (9.10, 11.15) | 0.61(0.55,0.65) | |
| Female | 52781.19 (49648.93, 54381.48) | 7.33 (6.94, 7.54) | 111017.56 (94842.84, 124128.50) | 8.92 (7.80 9.94) | 0.74(0.71,0.79) | |
| Male | 52496.51 (51122.75, 53345.66) | 10.44 (10.13, 16.61) | 109831.11 (98735.02, 121552.80) | 11.56 (10.39, 12.84) | 0.42(0.37,0.46) | |
| LAC | ||||||
| Total | 8816.52 (8498.10, 8816.52) | 4.33 (4.13, 4.45) | 32775.38 (29512.75, 35907.93) | 5.90 (5.34, 6.44) | 1.07(0.96,1.18) | |
| Female | 4402.31 (4208.34, 4537.44) | 4.21 (3.97, 4.36) | 17004.29 (15115.93, 18857.29) | 5.68 (5.06, 6.26) | 1.01(0.88,1.15) | |
| Male | 4414.20 (4285.43, 4527.37) | 4.43 (4.26, 4.56) | 15771.09 (14142.01, 17403.21) | 6.12 (5.51, 6.75) | 1.13(1.05,1.22) | |
| NAME | ||||||
| Total | 4518.57 (3840.51, 5331.35) | 2.70 (2.27, 3.19) | 22236.50 (19272.98, 25716.35) | 5.33 (4.64, 6.12) | 2.52(2.33,2.67) | |
| Female | 1691.06 (1450.80, 2090.37) | 2.09 (1.77, 2.63) | 8778.43 (7371.550, 10180.62) | 4.41 (3.69, 5.19) | 2.65(2.57,2.74) | |
| Male | 2827.51 (2265.03, 3589.42) | 3.29 (2.64, 4.15) | 13458.07 (11660.79, 15594.46) | 6.20 (5.43, 7.16) | 2.39(2.16,2.62) | |
| SA | ||||||
| Total | 7581.95 (6135.46, 8935.49) | 1.42 (1.14, 1.68) | 38730.75 (34042.52, 43731.61) | 2.86 (2.51, 3.24) | 2.45(2.35,2.56) | |
| Female | 2895.59 (2316.70, 3644.37) | 1.16 (0.90, 1.48) | 19123.29 (15850.60, 22411.77) | 2.78 (2.32, 3.27) | 3.06(2.92,3.21) | |
| Male | 4686.35 (3530.27, 5999.11) | 1.66 (1.24, 2.11) | 19607.46 (16233.85, 23082.42) | 2.94 (2.44, 3.47) | 2.02(1.95,2.09) | |
| SAEAO | ||||||
| Total | 33929.83 (30223.69, 37663.31) | 2.99 (2.67, 3.37) | 145113.31 (126581.05, 165495.71) | 5.46 (4.76, 6.26) | 2.27(2.12,2.42) | |
| Female | 14185.27 (12343.33, 16080.88) | 2.45 (2.13, 2.76) | 60461.51 (50268.47, 71697.83) | 4.32 (3.59, 5.12) | 2.01(1.86,2.14) | |
| Male | 19744.55 (16503.77, 23161.31) | 3.60 (3.04, 4.18) | 84651.80 (69347.53, 101702.30) | 6.76 (5.58, 8.46) | 2.50(2.33,2.66) | |
| SSA | ||||||
| Total | 4917.78 (4196.56, 5576.02) | 2.43 (2.08, 2.77) | 17097.42 (15181.29, 19333.42) | 3.95 (3.56, 4.41) | 1.60(1.53,1.66) | |
| Female | 2100.67 (1787.90, 2490.40) | 2.07 (1.76, 2.47) | 8620.92 (7450.33, 9847.70) | 3.80 (3.30, 4.39) | 2.06(2.02,2.11) | |
| Male | 2817.11 (2311.86, 3283.03) | 2.79 (2.30, 3.24) | 8476.49 (7363.74, 9738.55) | 4.11 (3.60, 4.68) | 1.22(1.12,1.33) | |
Note: UI Uncertainty Interval; ASIR Age-standardized incidence rate; EAPC Estimated Annual Percentage Change; CI Confidence Interval; CEEECA Central Europe, Eastern Europe, and Central Asia, HI High Income, LAC Latin America and Caribbean, NAME North Africa and Middle East, SA South Asia, SAEAO Southeast Asia, East Asia, and Oceania, SSA Sub-Saharan Africa